|
|
|
市場調査レポート
世界における創薬技術動向
Drug Discovery Technologies
|
Abstract
This report analyzes the worldwide markets for Drug Discovery Technologies in
Millions of US$. The specific technology types analyzed are Bioanalytical
Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics,
Bioinformatics, Pharmacogenomics, and Other Drug Discovery Technologies
(Include Combinatorial Chemistry, Nanotechnology and RNAi). The report
provides separate comprehensive analytics for the US, Canada, Japan, Europe
and Rest of World. Annual forecasts are provided for each region for the
period of 2001 through 2015. The report profiles 187 companies including many
key and niche players worldwide such as Abbott Laboratories, Affymetrix Inc.,
Agilent Technologies Inc., Albany Molecular Research, Inc., Amersham
Biosciences, Applera Corporation, ArQule Inc., AstraZeneca, BD Biosciences,
Bio-Rad Laboratories, Inc., BioSciences Group, Caliper Life Sciences, Inc.,
Capital GenomiX, Caprion Pharmaceuticals Inc., Charles River Laboratories
International, Inc., ChemBridge Corporation, deCODE Genetics, Inc., Evotec AG,
Galapagos NV, Incyte Corporation (Formerly Incyte Genomics, Inc.), Infinity
Pharmaceuticals, Inc., Invitrogen Corporation, Medarex, Inc., Merck & Co.,
Inc., Millennium Pharmaceuticals, Inc., National Center for Drug Screening,
PerkinElmer, Inc., Pharmacopeia Inc., Proteome Systems, Quantum
Pharmaceuticals, Shimadzu Corporation, Sigma-Aldrich, Tecan Group, Thallion
Pharmaceuticals, Inc. and Tripos, International. Market data and analytics are
derived from primary and secondary research. Company profiles are mostly
extracted from URL research and reported select online sources.
Table of Contents
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
- Bioanalytical Instruments
- Nuclear Magnetic Resonance
- Mass Spectroscopy
- Microplate Readers
- Chemotherapy Instruments
- High Throughput Screening (HTS)
- Genomics
- Proteomics
- Bioinformatics
- Biochip
- Pharmacogenomics
- Other Drug Discovery Technologies
II. EXECUTIVE SUMMARY
1. Industry Overview
- Drug Discovery Outsourcing - A Necessity
- Current & Future Analysis
- Analysis by Geographic Region
- Analysis by Technology Type
2. An Overview of Key Emerging Technologies
- Bioinformatics
- Pharmacogenomics
- Theragnostics
- Targeted Therapy
- Mass Spectrometry - A New Catalyst for Technological Developments
3. Market Trends
- New Technologies Fire Up Drug Discovery Market
- Obesity Related Diseases Driving Drug Discovery Research
- Biochips Change Face of Drug Discovery
- Genomics and Proteomics Gaining Prominence
- Genomics Drives Bioinformatics Growth in Drug Discovery
- Market Scenario of Human Genome Sciences (HGS)
- International Initiatives Expand Proteomics
4. Drug Discovery - An Overview
- Drug Discovery - Definition
- Drug Discovery Process
- Drug Discovery Technologies
- Bioanalytical Instruments
- Nuclear Magnetic Resonance
- Mass Spectroscopy
- Microplate Readers
- Chemotherapy Instruments
- High Throughput Screening
- Genomics
- Functional Genomics
- Structural Genomics
- Proteomics
- Classification of Proteomics
- Bioinformatics
- Categories of Bioinformatics
- Advantages of Bioinformatics in Drug Discovery
- Market Highlights
- Biochip
- Types of Biochips
- Pharmacogenomics
- A Revolutionary Health Care Therapy
- Other Drug Discovery Technologies
- Combinatorial Chemistry
- Lab-on-a-Chip
- RNA Interference
5. Product Launches
- Affymetrix Introduces Cytogenetic Solution
- Affymetrix Introduces DMET Early Access Solution
- Affymetrix Microarray Platform to feature in Pathwork' s Diagnostic Test
- Bio-Rad Laboratories Rolls Out Vasculitis Kit for BioPlex 2200 System
- PerkinElmer Develops Products for High-Throughput Screening
- Tecan to Introduce Multimode Microplate Reader- Infinite M1000
- Waters Introduces Next-Generation MS System - Synapt(tm)
- Tripos International Launches SYBYL(r)8.0
- Bio-Rad Laboratories Unveils In2it A1C Analyzer for Diabetic Patients
- Charles River Launches Endosafe(r)-MCS(tm) Endotoxin Detection System
- Invitrogen Launches Human Embryonic Stem Cells Monitoring Kit
- Sigma-Aldrich Introduces Proteomics Dynamic Range Standard
- Molecular Devices Develops Arcturus (XT) (tm) LMC Instrument
- Fujitsu' s BioSciences Renames CAChe Software and Releases Scigress
Explorer(tm)
- Tripos International Unveils Topomer CoMFA(r)
- Tripos International Launches Topomer Search
- Sigma-Aldrich Introduces GenomePlex(r)
- Agilent Unveils Dual Mode Microarray Platform
- Molecular Devices Launches ImageXpressULTRA(tm)
- Applied Biosystems Commercializes TaqMan(r) Influenza
- Agilent Launches Assay Kits for Lab-On-a-Chip Platform
- Affymetrix Unveils GeneChip(r) Microarrays
- Quantum Introduces Drug Discovery Software
- Invitrogen Launches Stealth(tm) RNAi Human Kinase Collection
- PerkinElmer Unveils BioXPRESSION(tm)
- Affymetrix and ParAllele Jointly Introduce MegAllele(tm) Assays
- Agilent Launches HD-CGH Custom Microarrays
- Applied Biosystems and MDS Sciex Unveil Tempo(tm) LC
- Beckman Coulter Presents Chemistry Analyzer for Clinical Testing
- Molecular Devices Launches ADME Assay Kits
- Applied Biosystems Unveils LS*LIMS(tm) Software
- Affymetrix Presents NimbleExpress(tm)
- Agilent Releases Software for Pharma QC/QA
6. Recent Industry Activity
- Affymetrix Acquires USB Corp
- Roche Acquires Ventana Medical Systems
- Bruker BioSciences Acquires Bruker BioSpin Group
- Takeda Signs Agreement to Take Over Millennium
- Pfizer to Acquire Serenex
- Implant Sciences to Acquire Ion Metrics
- NascaCell and Archemix Expand Partnership for Aptamer-Based Drugs
- DiscoveRx and Cosmo Bio Sign Distribution Agreement
- Zydus Cadila Enters into Collaboration with Prolong Pharmaceuticals
- PsychoGenics Enters into Drug Discovery Agreement with Dainippon
- Zydus Cadila Collaborates with Karo Bio
- Nicholas Piramal' s R&D Unit Extends Alliance with Eli Lilly
- Dr. Reddy' s Signs Collaboration Agreement with 7TM Pharma
- Synamatix Enters into Collaboration with Universiti Malaysia
- Monogram Enters into Exclusive Collaboration Agreement with Avexa
- Caliper Life Sciences Collaborates with Horizon Discovery
- Galapagos Signs Collaborative Agreement with Allergan for Drug Discovery
- Sigma-Aldrich Inks Exclusive Distribution Partnership with Atlas Antibodies
- PsychoGenics Enters into New Agreement with Eli Lilly
- Ambrx and Eli Lilly Enter into Alliance for Drug Discovery
- BioSeek Enters into Agreement with Dainippon Sumitomo
- NicOx Extends Collaboration with Pfizer
- BioFocus DPI Extends Contract with Lilly
- Invitrogen to Collaborate with Tecan
- Ranbaxy Forms New Drug Discovery Company
- Protagen to Expand Protein Biochips Business
- Znomics Expands Facilities for Drug Discovery
- Eli Lilly Acquires ICOS Corporation
- CMC Announces Acquisition of ICOS Biologics Facility from Eli Lilly
- SurModics Acquires Brookwood
- Commonwealth Biotechnologies Acquires Tripos Discovery Research
- VASTox Acquires Dextra Laboratories and Daniolabs
- Takeda Completes Acquisition of Paradigm
- Wyeth Completes the Acquisition of Haptogen
- Roche Takes Over Nimblegen
- AMRI Acquires Pharmaceutical Manufacturing Units in India
- Morvus Acquires Cardiff Biologicals and ProTides
- Agilent Technologies Acquires Stratagene
- AstraZeneca Takes Over MedImmune
- Ocimum Acquires Gene Logic' s Genomics Business
- Newsham Genetics Acquires Monsanto Choice Genetics
- Evotec Takes Over Combinature Biopharm' s Drug Discovery Unit
- BioServe Takes Over Genomics Collaborative
- Thomson Takes Over Unleashed Informatics Ltd
- Thomson Completes Acquisition of Prous Science
- MDS Acquires Molecular Devices
- Evotec to Take over Renovis
- Ecopia Merges with Caprion
- Domainex Merges with NCE Discovery
- Thallion Sells Majority Interest in Caprion Proteomics Business
- Affymetrix Enters into Licensing Agreement with Empire Genomics
- Graffinity Pharmaceuticals Signs Drug Discovery Agreement with Amgen
- ArQule Signs License Deal with Kyowa Hakko
- Toshiba, Canon and Others to Join Forces to Develop Biochips
- Orion and ChemDiv Enter into Collaborative Deal
- Graffinity Enters into Drug Discovery Collaboration with Pfizer
- Tata Enterprise Establishes Pharmaceutical Development Centre
- Nicholas Piramal Collaborates with Merck
- Eksigent Signs Distribution Agreement with Interface Engineering
- LEAD Therapeutics Enters Collaboration with Shang Pharma
- MDS Pharma Expands Chinese Lab Operations
- Ambit Extends Drug Discovery Collaboration with Bristol - Myers Squibb
- PsychoGenics Enters into Agreement with Cephalon for Drug Discovery
- Abbott and Caprion Proteomics Extends Partnership
- Agilent Technologies and BioNanomatrix Enters into Collaboration
- Evotec Extends Partnership with Boehringer Ingelheim
- Evotec and Interprotein Enter into Collaboration
- Galapagos Forms Drug Innovation Alliance with AstraZeneca
- Proteome Systems and BD Enter into an Agreement
- Galapagos Extends Drug Innovation Partnership with Amgen
- Dimerix Collaborates with NCDS
- ACE BioSciences and CLC Bio Enter into Collaborative Agreement
- Ambrx Enters into Strategic Agreement with Merck & Co
- Galapagos and Cystic Fibrosis Collaborate for Drug Discovery
- BioDiscovery Collaborates with Illumina
- Advinus Collaborates with DNDi
- Jubilant & Forest Enter into Partnership Deal
- Cisbio to Employ Lumi4(tm) Technology of Lumiphore
- Invitrogen Corporation Signs Agreement with Emiliem to Screen Kinase
Inhibitors
- AMRI Establishes New Center in India
- Actavis Takes Over Abrika
- Galapagos Announces Acquisition of Inpharmatica
- PerkinElmer Acquires Proteomics Technology from Agilix
- BD Finishes Acquisition of GeneOhm
- Albany Acquires ComGenex in Hungary
- Agilent Acquires Yokogawa
- Strand Forms Partnership with Microsoft BioIT Alliance
- Nicholas Piramal Signs License Agreement with Morvus Technology
- Cellomics and Evotec Sign a Patent License Agreement
- PerkinElmer Opens New Technology Center in Shanghai
- Affymetrix Acquires ParAllele
- Agilent Acquires Computational Biology
- MultiCell and Living Cell Enter into a Joint Venture
- Fujitsu and Ensemble Enter into Licensing Agreement
- Structural GenomiX Modifies Licensing Agreement with Lilly
- Provid Enters into Research Services Agreement with Palatin
- NascaCell Signs Co-marketing Agreement with DPI
- Evotec and P&G Sign Supply Agreement
- Invitrogen Signs Collaborative Agreement with NCDS
- HistoRx Enters into Collaboration with Eli Lilly
- Invitrogen and Applied Biosystems Forge Strategic Alliance
- UCB and ChemBridge Form Collaboration in Discovery Chemistry
- Pharmacopeia and CV Therapeutics Form Drug Discovery and Development
Collaboration
- OriGene Enters into Collaboration with Cytomyx
- Discovery Partners Divests Discovery Systems Business to Nexus
- CRL Acquires River Valley Farms
- Agilent Acquires Silicon
- Medarex Acquires Ability Biomedical
- National Instruments Enters into Joint Venture Agreement with Agilent
- Amersham Enters into 3-Year Distribution Agreement with Guava
- ChemBridge Signs an Agreement with Merck & Co.
- Bristol-Myers Collaborates with MEDX
- Bayer Enters into Partnership with Physiomics
- Pharmacopeia Spins-Off Pharmacopeia Drug Discovery
- Abbott Enters into Collaboration with Caprion
- Vertex Divests Instrumentation Assets to Aurora
7. Focus on Select Global Players
- Abbott Laboratories (US)
- Affymetrix Inc. (US)
- Agilent Technologies Inc. (US)
- Albany Molecular Research, Inc. (US)
- Amersham Biosciences (US)
- Applera Corporation (US)
- ArQule Inc. (US)
- AstraZeneca (UK)
- BD Biosciences (US)
- Bio-Rad Laboratories, Inc. (US)
- BioSciences Group (Japan)
- Caliper Life Sciences, Inc. (US)
- Capital GenomiX (US)
- Caprion Proteomics (Canada)
- Charles River Laboratories International, Inc. (US)
- ChemBridge Corporation (US)
- deCODE Genetics, Inc (Iceland)
- Evotec AG (Germany)
- Galapagos NV (Belgium)
- Incyte Corporation (Formerly Incyte Genomics Inc.) (US)
- Infinity Pharmaceuticals, Inc. (US)
- Invitrogen Corporation (US)
- Medarex, Inc. (US)
- Merck & Co., Inc. (US)
- Millennium Pharmaceuticals, Inc. (US)
- National Center for Drug Screening (China)
- PerkinElmer, Inc. (US)
- Pharmacopeia Inc. (US)
- Proteome Systems (Australia)
- Quantum Pharmaceuticals (Russia)
- Shimadzu Corporation (Japan)
- Sigma-Aldrich (US)
- Tecan Group (Switzerland)
- Thallion Pharmaceuticals, Inc. (Canada)
- Tripos International (US)
8. Global Market Perspective
- Table 1: World Recent Past, Current & Future Analysis for Drug
Discovery Technologies by Geographic Region - US, Canada, Japan, Europe and
Rest of World Markets Independently Analyzed with Annual Sales in US$ Million
for Years 2001 through 2010 (includes corresponding Graph/Chart)
- Table 2: World Long-term Projections for Drug Discovery Technologies by
Geographic Region - US, Canada, Japan, Europe and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for Years 2011 through
2015 (includes corresponding Graph/Chart)
- Table 3: World 10-Year Perspective for Drug Discovery Technologies by
Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan,
Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart)
- Analytics by Drug Discovery Technology Type
- Table 4: World Recent Past, Current & Future Analysis for
Bioanalytical Instruments by Geographic Region - US, Canada, Japan, Europe and
Rest of World Markets Independently Analyzed with Annual Sales in US$ Million
for Years 2001 through 2010 (includes corresponding Graph/Chart)
- Table 5: World Long-term Projections for Bioanalytical Instruments by
Geographic Region - US, Canada, Japan, Europe and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for Years 2011 through
2015 (includes corresponding Graph/Chart)
- Table 6: World 10-Year Perspective for Bioanalytical Instruments by
Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan,
Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart)
- Table 7: World Recent Past, Current & Future Analysis for High
Throughput Screening (HTS) by Geographic Region - US, Canada, Japan, Europe
and Rest of World Markets Independently Analyzed with Annual Sales in US$
Million for Years 2001 through 2010 (includes corresponding Graph/Chart)
- Table 8: World Long-term Projections for High Throughput Screening (HTS)
by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for Years 2011 through
2015 (includes corresponding Graph/Chart)
- Table 9: World 10-Year Perspective for High Throughput Screening (HTS) by
Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan,
Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart)
- Table 10: World Recent Past, Current & Future Analysis for Biochip by
Geographic Region - US, Canada, Japan, Europe and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for Years 2001 through
2010 (includes corresponding Graph/Chart)
- Table 11: World Long-term Projections for Biochip by Geographic Region -
US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart)
- Table 12: World 10-Year Perspective for Biochip by Geographic Region -
Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of
World Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart)
- Table 13: World Recent Past, Current & Future Analysis for Proteomics
by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for Years 2001 through
2010 (includes corresponding Graph/Chart)
- Table 14: World Long-term Projections for Proteomics by Geographic Region
- US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart)
- Table 15: World 10-Year Perspective for Proteomics by Geographic Region -
Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of
World Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart)
- Table 16: World Recent Past, Current & Future Analysis for Genomics by
Geographic Region - US, Canada, Japan, Europe and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for Years 2001 through
2010 (includes corresponding Graph/Chart)
- Table 17: World Long-term Projections for Genomics by Geographic Region -
US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart)
- Table 18: World 10-Year Perspective for Genomics by Geographic Region -
Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and Rest of
World Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart)
- Table 19: World Recent Past, Current & Future Analysis for
Bioinformatics by Geographic Region - US, Canada, Japan, Europe and Rest of
World Markets Independently Analyzed with Annual Sales in US$ Million for
Years 2001 through 2010 (includes corresponding Graph/Chart)
- Table 20: World Long-term Projections for Bioinformatics by Geographic
Region - US, Canada, Japan, Europe and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart)
- Table 21: World 10-Year Perspective for Bioinformatics by Geographic
Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and
Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart)
- Table 22: World Recent Past, Current & Future Analysis for
Pharmacogenomics by Geographic Region - US, Canada, Japan, Europe and Rest of
World Markets Independently Analyzed with Annual Sales in US$ Million for
Years 2001 through 2010 (includes corresponding Graph/Chart)
- Table 23: World Long-term Projections for Pharmacogenomics by Geographic
Region - US, Canada, Japan, Europe and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart)
- Table 24: World 10-Year Perspective for Pharmacogenomics by Geographic
Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe and
Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart)
- Table 25: World Recent Past, Current & Future Analysis for Other Drug
Discovery Technologies by Geographic Region - US, Canada, Japan, Europe and
Rest of World Markets Independently Analyzed with Annual Sales in US$ Million
for Years 2001 through 2010 (includes corresponding Graph/Chart)
- Table 26: World Long-term Projections for Other Drug Discovery
Technologies by Geographic Region - US, Canada, Japan, Europe and Rest of
World Markets Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 27: World 10-Year Perspective for Other Drug Discovery Technologies
by Geographic Region - Percentage Breakdown of Value Sales for US, Canada,
Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012
(includes corresponding Graph/Chart)
III. MARKET
1. The United States
- A. Market Analysis
- Overview
- US Leads the World High Throughput Screening (HTS) Market
- Current & Future Analysis
- Product Launches
- Strategic Corporate Developments
- Focus on Select US Players
- Abbott Laboratories
- Affymetrix Inc.
- Agilent Technologies Inc.
- Albany Molecular Research, Inc.
- Amersham Biosciences
- Applera Corporation
- ArQule Inc.
- BD Biosciences
- Bio-Rad Laboratories, Inc.
- Caliper Life Sciences, Inc.
- Capital GenomiX
- Charles River Laboratories International, Inc.
- ChemBridge Corporation
- deCODE Genetics, Inc.
- HistoRx, Inc.
- Incyte Corporation (Formerly Incyte Genomics Inc.)
- Infinity Pharmaceuticals, Inc.
- Invitrogen Corporation
- Medarex, Inc.
- Merck & Co., Inc.
- Millennium Pharmaceuticals, Inc.
- PerkinElmer, Inc.
- Pharmacopeia Inc..
- Provid Pharmaceuticals, Inc.
- Tigris Pharmaceuticals, Inc.
- Sigma-Aldrich
- Tripos International.
- B. Market Analytics
- Table 28: US Recent Past, Current & Future Analysis for Drug
Discovery Technologies by Technology Type - Bioanalytical Instruments, HTS,
Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other
Markets Independently Analyzed with Annual Sales in US$ Million for Years
2001 through 2010 (includes corresponding Graph/Chart)
- Table 29: US Long-term Projections for Drug Discovery Technologies by
Technology Type - Bioanalytical Instruments, High Throughput Screening
(HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and
Other Markets Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 30: US 10-Year Perspective for Drug Discovery Technologies by
Technology Type - Percentage Breakdown of Value Sales for Bioanalytical
Instruments, HTS, Biochip, Proteomics, Genomics, Bioinformatics,
Pharmacogenomics and Other Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart)
2. Canada
- A. Market Analysis
- Current & Future Analysis
- Strategic Corporate Developments
- Focus on Select Canadian Players
- Caprion Proteomics
- Thallion Pharmaceuticals, Inc.
- B. Market Analytics
- Table 31: Canadian Recent Past, Current & Future Analysis for Drug
Discovery Technologies by Technology Type - Bioanalytical Instruments, High
Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics,
Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2001 through 2010 (includes corresponding
Graph/Chart)
- Table 32: Canadian Long-term Projections for Drug Discovery Technologies
by Technology Type - Bioanalytical Instruments, High Throughput Screening
(HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and
Other Markets Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 33: Canadian 10-Year Perspective for Drug Discovery Technologies
by Technology Type - Percentage Breakdown of Value Sales for Bioanalytical
Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics,
Bioinformatics, Pharmacogenomics and Other Markets for Years 2003, 2008
& 2012 (includes corresponding Graph/Chart)
3. Japan
- A. Market Analysis
- Current & Future Analysis
- Japan Resembles US in Life Science Research
- Strategic Corporate Developments
- Focus on Select Japanese Players
- BioSciences Group
- Shimadzu Corporation
- B. Market Analytics
- Table 34: Japanese Recent Past, Current & Future Analysis for Drug
Discovery Technologies by Technology Type - Bioanalytical Instruments, High
Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics,
Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2001 through 2010 (includes corresponding
Graph/Chart)
- Table 35: Japanese Long-term Projections for Drug Discovery Technologies
by Technology Type - Bioanalytical Instruments, High Throughput Screening
(HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and
Other Markets Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 36: Japanese 10-Year Perspective for Drug Discovery Technologies
by Technology Type - Percentage Breakdown of Value Sales for Bioanalytical
Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics,
Bioinformatics, Pharmacogenomics and Other Markets for Years 2003, 2008
& 2012 (includes corresponding Graph/Chart)
4. Europe
- A. Market Analysis
- Current & Future Analysis
- An Overview of Pharmacogenomics and Personalized Medicine
- Emerging Trends in Proteomics Technology
- Protein Classification
- Protein Separation
- Market Trends
- European Market for Drug Discovery Tools
- UK Government Supports Proteomics Research
- Drug Discovery Outsourcing in Europe
- Recent Industry Activity
- Focus on Select European Players
- AstraZeneca (UK)
- deCODE Genetics, Inc (Iceland)
- Evotec AG (Germany)
- NascaCell IP GmbH (Germany)
- Quantum Pharmaceuticals (Russia)
- Tecan Group (Switzerland)
- UCB (Belgium)
- B. Market Analytics
- Table 37: European Recent Past, Current & Future Analysis for Drug
Discovery Technologies by Technology Type - Bioanalytical Instruments, High
Throughput Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics,
Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2001 through 2010 (includes corresponding
Graph/Chart)
- Table 38: European Long-term Projections for Drug Discovery Technologies
by Technology Type - Bioanalytical Instruments, High Throughput Screening
(HTS), Biochip, Proteomics, Genomics, Bioinformatics, Pharmacogenomics and
Other Markets Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 39: European 10-Year Perspective for Drug Discovery Technologies
by Technology Type - Percentage Breakdown of Value Sales for Bioanalytical
Instruments, High Throughput Screening (HTS), Biochip, Proteomics, Genomics,
Bioinformatics, Pharmacogenomics and Other Markets for Years 2003, 2008
& 2012 (includes corresponding Graph/Chart)
5. Rest of World
- A. Market Analysis
- Current & Future Analysis
- Asia-Pacific
- Emerging Opportunities
- Cost Advantage in Asia Attracts Global Drug Discovery Industry
- Regulations Affect Asia-Pacific Drug Discovery Market
- India
- Bioinformatics Market in India
- Scope and Demand for Bioinformatics Market to Expand Significantly by
2010
- Discovery of Therapeutic Molecules - A New Buzzword for Growth
Acceleration
- Strategic Corporate Developments
- Focus on Select Players
- National Center for Drug Screening (China)
- Proteome Systems (Australia)
- B. Market Analytics
- Table 40: Rest of World Recent Past, Current & Future Analysis for
Drug Discovery Technologies by Technology Type - Bioanalytical Instruments,
High Throughput Screening (HTS), Biochip, Proteomics, Genomics,
Bioinformatics, Pharmacogenomics & Other Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2001 through 2010 (includes
corresponding Graph/Chart)
- Table 41: Rest of World Long-term Projections for Drug Discovery
Technologies by Technology Type - Bioanalytical Instruments, High Throughput
Screening (HTS), Biochip, Proteomics, Genomics, Bioinformatics,
Pharmacogenomics and Other Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2011 through 2015 (includes corresponding
Graph/Chart)
- Table 42: Rest of World 10-Year Perspective for Drug Discovery
Technologies by Technology Type - Percentage Breakdown of Value Sales for
Bioanalytical Instruments, High Throughput Screening (HTS), Biochip,
Proteomics, Genomics, Bioinformatics, Pharmacogenomics and Other Markets for
Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
COMPETITIVE LANDSCAPE
|
 |
